Voro Therapeutics
Voro Therapeutics is a privately held biotechnology company based in San Diego and Boston, spun out of Alloy Therapeutics’ 82VS Venture Studio. PrimeBody™ is a next-generation tumor-activated biologics platform that enables systemic delivery with activation restricted to the tumor microenvironment, driving safer and more durable anti-tumor responses. Voro’s lead asset, the first Fc-enhanced, high-affinity CD47 blocker, shows curative activity without the historical safety or exposure limitations of this target and is advancing through IND-enabling studies with a defined clinical strategy. Applicable to cytokines, TCEs, and ADCs, PrimeBody™ supports a diversified pipeline.
7-day free trial · no credit card
Verified contacts
3
available on Kipplo
LinkedIn employees
9
1 to 10 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 3 verified contacts at Voro Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
3 contacts with verified email or phone · masked until revealed.
- AS
Aaron Springer
, - · Other
EmailPhone - UE
Ugur Eskiocak
CEO & Co-founder · General Business & Management
EmailPhone
Showing 2 of 3 verified contacts
Top roles at Voro Therapeutics
2 distinct titles indexed · top 2 shown.
- 1, -
- 1ceo & co-founder
Sign up to unlock all 3 contacts at Voro Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 3 verified contacts at Voro Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.